TOP2A and breast cancer: There was sparse evidence from level III retrospective studies and level IV pre-clinical studies supporting the chemosensitizing effect of TOP1 and TOP2A overexpression in response to camptothecin-based therapies and anthracyclines in gastrointestinal and breast cancers respectively.